Navigation Links
Lexicon Announces Pricing of Common Stock in Public Offering
Date:10/8/2009

THE WOODLANDS, Texas, Oct. 8 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the pricing of a public offering of 33,333,333 shares of its common stock at $1.50 per share, of which 19,894,076 shares are being offered through the underwriters and 13,439,257 shares are being offered to Invus, L.P., Lexicon's largest stockholder. All of the shares are being offered by Lexicon pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. Lexicon has also granted the underwriters a 30-day option to purchase up to an aggregate of 2,984,111 additional shares of common stock to cover over-allotments, if any. Morgan Stanley is acting as the sole book-runner for the offering, with Thomas Weisel Partners LLC acting as co-manager.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted. The offering of these securities will be made only by means of a final prospectus supplement and accompanying prospectus, copies of which may be obtained from Morgan Stanley & Co. Incorporated, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, telephone: (866) 718-1649, or by emailing prospectus@morganstanley.com.

The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and related prospectus supplements and other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements related to Lexicon's expectations regarding the completion, timing and size of the public offering. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "anticipated," "will," "proposed," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Lexicon's results to differ materially from those indicated by these forward-looking statements, including risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering. There can be no assurance that Lexicon will be able to complete the public offering on the anticipated terms, or at all. Additional risks and uncertainties relating to the public offering, Lexicon and its business can be found under the headings "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission and under the heading "Risk Factors" in the final prospectus supplement related to the public offering to be filed with the Securities and Exchange Commission on October 8, 2009. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
3. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
4. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
5. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
6. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
7. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Mirixa Corporation Announces Key Pharmacy Network Hire
10. Cold Spring Publishing Announces the Launch of a New Oncology Publication: The Journal of the Advanced Practitioner in Oncology
11. Advanced Health Media Announces Acquisition of Ephikacy, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... YORK , March 24, 2017 ... and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic ... Heart Inc. (NASDAQ: SSH ). These companies are ... its prior gains on Thursday, March 23 rd , 2017, ... afternoon, while shares of health care companies in the S&P ...
(Date:3/24/2017)... 2017  HealthMine surveys with 9,250 insured consumers fielded ... plan members want help from their plans in five ... their health, 2) help closing gaps in care, 3) ... and 5) relevant, real-time guidance. Meeting these needs is ... A Reason to Stay Engaged ...
(Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA (OSE: ... complete 2016 Annual Accounts with notes. The report is attached ... the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, please ... Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media enquiries: ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... “Finding Christ Through Social Media: Year One #A365DayJourney to ... path toward true communion with God. “Finding Christ Through Social Media: Year One ... published author Lea Michelle Johnson, a follower of Christ, wife and mother who ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: ... of God in congregations across the United States. “The Communion of Saints” ... 1964 who has served congregations in seven states throughout his long career of ...
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates ... based on a review of GPA and SAT/ACT requirements at 221 institutions in 25 ... argues that this higher bar should be set by states, by the Council for ...
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... ... ... The MBI “Hall of Fame” recognizes the contributions of those whose careers are or were ... careers of all others involved. , On Monday, March 21st, 2017 Laurie Robert, ... Fame. The induction took place during the World of Modular – Award Gala in ...
Breaking Medicine News(10 mins):